

# John LÃ¶fblom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2118526/publications.pdf>

Version: 2024-02-01

82  
papers

3,038  
citations

172457

29  
h-index

175258

52  
g-index

84  
all docs

84  
docs citations

84  
times ranked

3061  
citing authors

#	ARTICLE	IF	CITATIONS
1	Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters, 2010, 584, 2670-2680.	2.8	521
2	Affibody Molecules in Biotechnological and Medical Applications. Trends in Biotechnology, 2017, 35, 691-712.	9.3	259
3	Optimization of electroporation-mediated transformation: Staphylococcus carnosus as model organism. Journal of Applied Microbiology, 2007, 102, 736-747.	3.1	132
4	Optimizing Membrane Protein Overexpression in the Escherichia coli strain Lemo21(DE3). Journal of Molecular Biology, 2012, 423, 648-659.	4.2	132
5	Non-immunoglobulin based protein scaffolds. Current Opinion in Biotechnology, 2011, 22, 843-848.	6.6	128
6	Epitope mapping of antibodies using bacterial surface display. Nature Methods, 2008, 5, 1039-1045.	19.0	90
7	Bacterial display in combinatorial protein engineering. Biotechnology Journal, 2011, 6, 1115-1129.	3.5	90
8	A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Engineering, Design and Selection, 2008, 21, 247-255.	2.1	68
9	Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Engineering, Design and Selection, 2011, 24, 385-396.	2.1	62
10	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification. PLoS ONE, 2013, 8, e62791.	2.5	61
11	Affibody-mediated PET imaging of HER3 expression in malignant tumours. Scientific Reports, 2015, 5, 15226.	3.3	56
12	Surface display of a single-domain antibody library on Gram-positive bacteria. Cellular and Molecular Life Sciences, 2013, 70, 1081-1093.	5.4	53
13	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. International Journal of Oncology, 2016, 48, 1325-1332.	3.3	50
14	Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to Albumin. PLoS ONE, 2014, 9, e103094.	2.5	50
15	Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotechnology Journal, 2014, 9, 1215-1222.	3.5	46
16	Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display. FEMS Microbiology Letters, 2005, 248, 189-198.	1.8	45
17	An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17110-17115.	7.1	43
18	Evaluation of Staphylococcal Cell Surface Display and Flow Cytometry for Postselectional Characterization of Affinity Proteins in Combinatorial Protein Engineering Applications. Applied and Environmental Microbiology, 2007, 73, 6714-6721.	3.1	40

#	ARTICLE	IF	CITATIONS
19	Imaging of HER3-expressing xenografts in mice using a <sup>99m</sup> Tc(CO) <sub>3</sub> -HEHEHE-ZHER3:08699 affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1450-1459.	6.4	40
20	Cellular Effects of HER3-Specific Affibody Molecules. <i>PLoS ONE</i> , 2012, 7, e40023.	2.5	39
21	Engineering Bispecificity into a Single Albumin-Binding Domain. <i>PLoS ONE</i> , 2011, 6, e25791.	2.5	37
22	Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. <i>MAbs</i> , 2016, 8, 1195-1209.	5.2	37
23	<i>Staphylococcus carnosus</i> : from starter culture to protein engineering platform. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 8293-8307.	3.6	36
24	A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-β aggregation inhibitors with subnanomolar affinity. <i>Biotechnology Journal</i> , 2015, 10, 1707-1718.	3.5	35
25	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. <i>Molecular Pharmaceutics</i> , 2019, 16, 995-1008.	4.6	35
26	Optimal composition and position of histidine-containing tags improves biodistribution of <sup>99m</sup> Tc-labeled DARPin G3. <i>Scientific Reports</i> , 2019, 9, 9405.	3.3	34
27	Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. <i>Scientific Reports</i> , 2014, 4, 7518.	3.3	31
28	Cyclic versus Noncyclic Chelating Scaffold for <sup>89</sup> Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. <i>Molecular Pharmaceutics</i> , 2018, 15, 175-185.	4.6	31
29	Comparative evaluation of <sup>111</sup> In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. <i>Oncology Reports</i> , 2015, 34, 1042-1048.	2.6	30
30	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. <i>Molecular Pharmaceutics</i> , 2016, 13, 3676-3687.	4.6	30
31	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. <i>Scientific Reports</i> , 2017, 7, 5961.	3.3	29
32	Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 3973-3985.	5.4	28
33	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with <sup>99m</sup> Tc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , 2016, 49, 2285-2293.	3.3	27
34	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. <i>Theranostics</i> , 2018, 8, 4462-4476.	10.0	25
35	<sup>188</sup> Re-Z <sub>HER2:V2</sub> , a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1842-1848.	5.0	23
36	Staphylococcal Surface Display in Combinatorial Protein Engineering and Epitope Mapping of Antibodies. <i>Recent Patents on Biotechnology</i> , 2010, 4, 171-182.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Preclinical Evaluation of [ <sup>68</sup> Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. <i>Cells</i> , 2018, 7, 141.	4.1	21
38	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of <sup>68</sup> Ga-Labeled Tracers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1080.	4.1	21
39	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , 2017, 7, 43118.	3.3	20
40	An engineered autotransporter-based surface expression vector enables efficient display of Affibody molecules on OmpT-negative <i>E. coli</i> as well as protease-mediated secretion in OmpT-positive strains. <i>Microbial Cell Factories</i> , 2014, 13, 179.	4.0	19
41	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with <sup>188</sup> Re. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 519-528.	5.5	19
42	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. <i>Cells</i> , 2018, 7, 164.	4.1	19
43	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. <i>Molecular Pharmaceutics</i> , 2018, 15, 3394-3403.	4.6	19
44	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. <i>International Journal of Oncology</i> , 2019, 54, 1209-1220.	3.3	19
45	Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1671-1683.	5.4	18
46	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. <i>Scientific Reports</i> , 2019, 9, 655.	3.3	18
47	Exploring epitopes of antibodies toward the human tryptophanyl-tRNA synthetase. <i>New Biotechnology</i> , 2010, 27, 129-137.	4.4	17
48	A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 1405-1415.	5.4	17
49	Identification of proteins that specifically recognize and bind protofibrillar aggregates of amyloid- $\beta$ . <i>Scientific Reports</i> , 2017, 7, 5949.	3.3	17
50	Affinity proteins and their generation. <i>Journal of Chemical Technology and Biotechnology</i> , 2013, 88, 25-38.	3.2	16
51	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of <sup>99m</sup> Tc-labeled anti-EGFR affibody molecules. <i>Amino Acids</i> , 2018, 50, 981-994.	2.7	16
52	Affibody-Mediated Sequestration of Amyloid $\beta$ Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 64.	3.4	16
53	Staphylococcal display for combinatorial protein engineering of a head-to-tail affibody dimer binding the Alzheimer amyloid- $\beta$ peptide. <i>Biotechnology Journal</i> , 2013, 8, 139-145.	3.5	14
54	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. <i>Scientific Reports</i> , 2019, 9, 14907.	3.3	14

#	ARTICLE	IF	CITATIONS
55	Increase in negative charge of <sup>68</sup> Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. <i>Scientific Reports</i> , 2019, 9, 17710.	3.3	14
56	Parallel Immunizations of Rabbits Using the Same Antigen Yield Antibodies with Similar, but Not Identical, Epitopes. <i>PLoS ONE</i> , 2012, 7, e45817.	2.5	13
57	Simplified characterization through site-specific protease-mediated release of affinity proteins selected by staphylococcal display. <i>FEMS Microbiology Letters</i> , 2008, 278, 128-136.	1.8	12
58	An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2999.	4.1	12
59	Epitope Mapping Using Gram-Positive Surface Display. <i>Current Protocols in Immunology</i> , 2010, 90, Unit9.9.	3.6	11
60	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. <i>International Journal of Oncology</i> , 2017, 51, 1765-1774.	3.3	10
61	The Use of a Non-Conventional Long-Lived Gallium Radioisotope <sup>66</sup> Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. <i>Pharmaceutics</i> , 2021, 13, 292.	4.5	10
62	Insights from engineering the Affibody-Fc interaction with a computational-experimental method. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 593-601.	2.1	9
63	Autotransporter-Mediated Display of a Na <sup>+</sup> -ve Affibody Library on the Outer Membrane of <i>Escherichia coli</i> . <i>Biotechnology Journal</i> , 2019, 14, e1800359.	3.5	9
64	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. <i>Pharmaceutics</i> , 2020, 12, 551.	4.5	9
65	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1972.	4.1	9
66	Investigating affinity-maturation strategies and reproducibility of fluorescence-activated cell sorting using a recombinant ADAPT library displayed on staphylococci. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 187-195.	2.1	8
67	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , 2019, 9, 6779.	3.3	8
68	Directed evolution of the 3C protease from coxsackievirus using a novel fluorescence-assisted intracellular method. <i>Biological Chemistry</i> , 2019, 400, 405-415.	2.5	8
69	Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. <i>Scientific Reports</i> , 2021, 11, 19151.	3.3	8
70	Protease substrate profiling using bacterial display of self-blocking affinity proteins and flow-cytometric sorting. <i>Biotechnology Journal</i> , 2017, 12, 1600365.	3.5	7
71	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1312.	4.1	7
72	Robust Expression of the Human Neonatal Fc Receptor in a Truncated Soluble Form and as a Full-Length Membrane-Bound Protein in Fusion with eGFP. <i>PLoS ONE</i> , 2013, 8, e81350.	2.5	7

#	ARTICLE	IF	CITATIONS
73	A protease substrate profiling method that links site-specific proteolysis with antibiotic resistance. <i>Biotechnology Journal</i> , 2014, 9, 155-162.	3.5	6
74	HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. <i>Cancers</i> , 2021, 13, 4791.	3.7	6
75	Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches. <i>Scientific Reports</i> , 2020, 10, 18148.	3.3	5
76	Dissecting the Structural Organization of Multiprotein Amyloid Aggregates Using a Bottom-Up Approach. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1447-1457.	3.5	5
77	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. <i>Oncology Reports</i> , 2018, 41, 534-542.	2.6	4
78	Flow-cytometric screening of aggregation-inhibitors using a fluorescence-assisted intracellular method. <i>Biotechnology Journal</i> , 2017, 12, 1600364.	3.5	3
79	VEGFR2-Specific Ligands Based on Affibody Molecules Demonstrate Agonistic Effects when Tetrameric in the Soluble Form or Immobilized via Spider Silk. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 6474-6484.	5.2	2
80	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. <i>Biomedicines</i> , 2022, 10, 1293.	3.2	2
81	P3-050: An Affibody to Monomeric A $\beta$ as a Novel Therapeutic Approach for Alzheimer's Disease Pathology. , 2016, 12, P835-P836.		1
82	Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-A $\beta$ -Affibodies. <i>Pharmaceutical Research</i> , 2022, , 1.	3.5	1